Identification of Secondary Prevention Patients Eligible for PCSK9 Inhibitors Therapy According to the Routine Clinical Practice in Spain.

Juan Cosín SalesEduard SidelnikovSantiago VillamayorMiriam FernándezSandra Merino-MonteroAlberto Zamora

Published in: Advances in therapy (2022)

Up to 82% of patients with atherosclerotic CV disease do not achieve LDL-C levels recommended by the 2019 ESC/EAS guidelines despite being on optimized oral LLT therapy. In 17.9% of these patients LDL-C levels exceed 100 mg/dL, being eligible for PCSK9i in Spain.

Keyphrases

clinical practice
end stage renal disease
ejection fraction
chronic kidney disease
stem cells
cell therapy
patient reported